News | August 03, 2024
AbbVie completes acquisition of Cerevel Therapeutics
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program
Austin assumes role from Glenn F. Tilton, who will continue to serve as an independent director
PICCOLO trial met its primary endpoint of objective response rate (ORR)
Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD)
Further strengthens BaseLaunch's global pharma industry partnerships
Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders
Open a printable version of this pageEmail the URL of this page to a friend
Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine
Subscribe To Our Newsletter & Stay Updated
